Our consistent finding is a higher expression of EEF1A2 (breast, lung, prostate, pancreatic, liver) and reduced expression of EEF1A1 (breast, lung, gastric, kidney, head and neck) in most of the cancers, which is in accordance with previously reported findings from perturbation of EEF1A2, showing it as an oncogene in different cancers [7–9, 34, 40]. The gene discussed is EEF1A2; the disease is cancer.